Show simple item record

dc.contributor.authorShahzad Hasan, Syed
dc.contributor.authorHow, Chia Siang
dc.contributor.authorDawoud, Dalia M
dc.contributor.authorMohamed, Omneya
dc.contributor.authorBaines, Darrin
dc.contributor.authorBabar, Zaheer-Ud-Din
dc.date.accessioned2020-03-25T01:07:29Z
dc.date.available2020-03-25T01:07:29Z
dc.date.issued2019-05
dc.identifier.citationShahzad Hasan , S , How , C S , Dawoud , D M , Mohamed , O , Baines , D & Babar , Z-U-D 2019 , ' Pharmaceutical policy reforms to regulate drug prices in Asia Pacific Region: The case of Australia, China, India, Malaysia, New Zealand and South Korea ' , Value in Health Regional Issues , vol. 18 , pp. 18-23 . https://doi.org/10.1016/j.vhri.2018.08.007
dc.identifier.issn2212-1099
dc.identifier.urihttp://hdl.handle.net/2299/22469
dc.description© 2018 Elsevier. This manuscript is made available under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND 4.0). For further details please see: https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.abstractMedicine price directly affects affordability and access to medicines particularly in countries where a major portion of pharmaceutical spending is through out-of-pocket payment, such as in the Asia Pacific region. We have undertaken a detailed appraisal of the pharmaceutical policy reforms to regulate drug prices in 3 developed (Australia, New Zealand, and South Korea) and 3 emerging (China, India, and Malaysia) economies of the Asia Pacific region. Despite continuous efforts by the authorities in adopting a wide range of reformatory pharmaceutical pricing policies to ensure affordability of medicines, these policies may not be optimal where drug prices were not lowered as expected (eg, in Korea). On the contrary, considerable price reductions of various pharmaceuticals have been observed in New Zealand and India because of the reform in pharmaceutical pricing policy. This review of pharmaceutical pricing reforms reinforces the need for constant monitoring by policy makers in Asia Pacific countries to regulate drug prices and to undertake reform in pharmaceutical pricing policies when necessary to ensure affordability and access to medicines.en
dc.format.extent6
dc.format.extent391069
dc.language.isoeng
dc.relation.ispartofValue in Health Regional Issues
dc.subjectAccess
dc.subjectaffordability
dc.subjectpharmaceutical pricing
dc.subjectpharmaceutical policy
dc.subjectAsia
dc.subjectPACIFIC
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.titlePharmaceutical policy reforms to regulate drug prices in Asia Pacific Region: The case of Australia, China, India, Malaysia, New Zealand and South Koreaen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2019-11-07
rioxxterms.versionofrecord10.1016/j.vhri.2018.08.007
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record